AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...

Oct 27 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding ...

The MarketWatch News Department was not involved in the creation of this content. TOKYO, Oct. 21, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of ...

Megalin-targeting ligand-siRNA conjugates (megalin-STRIKERs) deliver siRNAs to proximal tubular epithelial cells (PTECs) in the kidney leading to target gene silencing across multiple targets Data ...

In a deal that could bring more than $2.1 billion in payments to Arbor Biotechnologies Inc., 90-year-old Chiesi Group gained exclusive and global rights to develop and commercialize ABO-101 for ...

BOSTON and SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ -- iNtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering ...

DRUMS WEEK 2025: Carnegie Hall, New York City, 16 January 1938. An eager audience is keyed up with excitement, awaiting the first jazz concert at this prestigious classical music venue. The Benny ...

A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies. His work was reviled as reckless and unethical because, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A St. Louis startup is ...

This media is in the public domain (free of copyright restrictions). You can copy, modify, and distribute this work without contacting the Smithsonian. For more information, visit the Smithsonian's ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Wilson, CEO of Gemma Bio, called ...

A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to ...